Johnson & Johnson’s prostate cancer drug shrinks tumors in early-stage trial
Summary
An early-stage clinical trial shows that Johnson and Johnson's new prostate cancer medication successfully reduces tumor size. Researchers are evaluating the drug's effectiveness and safety profile in these preliminary testing phases.
Source: Read the full story at Stock Market News
Disclaimer: This content is for informational and educational purposes only and is not financial, investment or trading advice. Tech & Money Press is not a registered investment adviser or broker-dealer. Trading stocks, options and crypto involves substantial risk, including the loss of your entire investment. Do your own research and consult a licensed professional before making any financial decision. The authors may hold positions in the securities mentioned. News summaries are written with AI assistance from the original publisher's report and may contain errors; always check the original source. Full disclaimer.